MRNA Stock Recent News
MRNA LATEST HEADLINES
The latest trading day saw Moderna (MRNA) settling at $33.64, representing a -1.87% change from its previous close.
Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to 11 years.
Shares of Moderna (NASDAQ:MRNA) have been long forgotten about since its demand for COVID shots fell off a cliff more than three years ago.
CAMBRIDGE, MA / ACCESS Newswire / July 11, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, August 1, 2025 to report its second quarter 2025 financial results, and provide a corporate update.
The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.'s MRNA supplemental Biologics License Application (sBLA) for Spikevax, the company's COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.
The U.S. Food and Drug Administration has granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the disease, the company said on Thursday.
Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19 disease CAMBRIDGE, MA / ACCESS Newswire / July 10, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Spikevax®, the Company's COVID-19 vaccine, in children 6 months through 11 years of age who are at increased risk for COVID-19 disease. The Company's COVID-19 vaccine, mRNA-1273, was previously available for pediatric populations under Emergency Use Authorization (EUA).
Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in the latest round of a long-running legal dispute between the two sides.
Major U.S. equities indexes finished the day mixed as investors worked through the latest developments in the trade policy saga.
MRNY's synthetic option strategy delivers high distributions but has led to severe capital losses, with price down over 83% in the past year. The capped upside and unlimited downside risk make MRNY unattractive unless Moderna's share price stabilizes and recovers meaningfully. Current distributions are high (near 100% yield), but payouts have shrunk and sustainability is questionable without a turnaround in MRNA.